Dr Afsar Mian has expertise in developing novel drugs and peptide therapies as targeted therapies against Leukaemia. ​His research is focused on understanding the mechanisms of treatment-resistant or refractory Leukaemia. ​​Dr Mian's research ​has resulted in the development of the PF-114 drug for treating resistant Leukaemia ​which is currently in phase III clinical trial. ​​His current research at AKU-CRM is focusing on developing a cell and peptide-based approach for treating Ph+ Leukaemia and developing a druggable gene editing therapy for beta-thalassemia and sickle cell anaemia.